

19 August 2025

Treatment of Cancers in Secondary Care

1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 01 April 2025 to the end of June 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
1.1 Abiraterone (Zytiga or generic abiraterone)	48
1.2 Apalutamide (Erleada)	36
1.3 Cabazitaxel (Jevtana or generic cabazitaxel)	6
1.4 Darolutamide (Nubeqa)	14
1.5 Enzalutamide (Xtandi)	165
1.6 Talazoparib (Talzenna)	<5
1.7 Docetaxel	Dingle Agent 5 In-Combo 91
1.8 Relugolix (Orgovyx, Ryego)	<5

2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 01 April 2025 to the end of June 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
2.1 Docetaxel for prostate cancer	12
2.2 Olaparib (Lynparza) for prostate cancer	<5
2.3 Talazoparib (Talzenna) for prostate cancer	<5
2.4 Relugolix (Orgovyx) for prostate cancer	<5

19 August 2025

3. How many patients received their first cycle or first dose of the following products in the 3 months between 01 April 2025 to the end of June 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated in Cycle 1 or Dose 1
3.1 Abiraterone (Zytiga or generic abiraterone)	6
3.2 Apalutamide (Erleada)	14
3.3 Cabazitaxel (Jevtana or generic cabazitaxel)	<5
3.4 Darolutamide (Nubeqa)	<5
3.5 Enzalutamide (Xtandi)	33

4. How many patients were treated with the following combinations in the 3 months between 01 April 2025 to the end of June 2025, or latest 3-months for which data are available? Please give total number of patients and number of patients receiving their first dose or first cycle.

Name of medicine	<u>Total</u> Number patients treated	Number patients received <u>cycle 1 or dose 1</u>
4.1 Darolutamide (Nubeqa) + Docetaxel + ADT	ADT information is not available on RISOH	
4.2 Darolutamide (Nubeqa) + ADT	ADT information is not available on RISOH	
4.2 Olaparib (Lynparza) + Abiraterone	<5	

Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuprorelin, triptorelin, degarelix, flutamide

5. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 01 April 2025 to the end of June 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
5.1 Abiraterone	48
5.2 Enzalutamide	165

19 August 2025

6. How many patients were treated in total, regardless of diagnosis, with the following medicines in the 3 months between 01 April 2025 and the end of June 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
6.1 Niraparib (Zejula)	59
6.2 Rucaparib (Rubraca)	<5
6.3 Olaparib (Lynparza)	25

7. How many patients were treated for ovarian, fallopian tube or primary peritoneal cancers, with the following medicines as monotherapy or in combination, in the 3 months between 01 April 2025 to the end of June 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
7.1 Olaparib in total	23
7.2 Olaparib monotherapy	23
7.3 Olaparib + bevacizumab in combination	<5
7.4 Bevacizumab total	10
7.5 Bevacizumab monotherapy	<5
7.6 Bevacizumab + carboplatin + paclitaxel, or bevacizumab + gemcitabine + carboplatin, or bevacizumab + paclitaxel + pegylated liposomal doxorubicin	Bevac+Pac 7 Bevac+NabPac <5

8. How many patients were treated for Endometrial Cancer, with the following medicines in the 3 months between 01 April 2025 and 30 June 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
8.1 Dostarlimab (Jemperli)	8
8.2 Pembrolizumab (Keytruda)	<5
8.3 Lenvatinib (Lenvima)	<5

19 August 2025

9. How many patients were treated for Endometrial Cancer, with the following medicines as monotherapy or in combination, in the 3 months between 01 April 2025 and 30 June 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated
9.1 Dostarlimab monotherapy	<5
9.2 Dostarlimab in combination with Chemotherapy	5
9.3 Pembrolizumab monotherapy	<5
9.4 Pembrolizumab + Lenvatinib in combination	<5
9.5 Pembrolizumab in combination with Chemotherapy	<5
9.6 Lenvatinib monotherapy	<5

N.B. Use of less than five (<5) - We are not able to provide the information requested. The low numbers involved would reduce numbers to discoverable limits and, as a result, we consider that individuals could be identified and disclosure of this information would breach the first data protection principle, which relates to the fair and lawful processing of personal data. Therefore, we have concluded that this information is exempt from disclosure under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party.